Wegovy® 7.2 mg in a single-dose pen has now been recommended by CHMP for approval in the EU Novo Nordisk expects to launch Wegovy® 7.2 mg in a single-dose pen in the EU in Q3 2026 In the STEP UP trial, Wegovy® 7.2 mg demonstrated an average weight loss of 20.7%1, and around one-third of patients achieved 25% or greater weight loss Wegovy® 7.2 mg is already available in the U.S. for adults living with obesity under the brand name Wegovy® HDBagsværd, Denmark, 22 May 2026 – Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorisation of Wegovy® 7.2 mg (once-weekly injectable semaglutide 7.2 mg) in a single-dose pen for people living with obesity. Wegovy® 7.2 mg is already available in the EU for...

Vancouver, British Columbia, May 22, 2026 (GLOBE NEWSWIRE) — NevGold Corp. (“NevGold” or the “Company”) (TSXV:NAU) (OTCQX:NAUFF) (Frankfurt:5E50) congratulates Perpetua Resources Corp. (TSX:PPTA, NASDAQ:PPTA, “Perpetua”) on the approved US$2.9 billion senior secured project loan from the Export-Import Bank of the United States (“EXIM”) (see Perpetua Resources News Release from May 21, 2026) under the “Make More in America Initiative”. The loan supports the development of the Stibnite gold‑antimony project in Idaho and represents a major commitment by the U.S. Government to rebuilding a secure domestic antimony supply chain. Perpetua’s Stibnite Project is currently the only large-scale, domestic resource of the Critical Mineral antimony. NevGold is rapidly advancing its maiden antimony-gold Mineral Resource Estimate (“MRE”) at the...

NORBIT today announces that its segment Connectivity has entered into an agreement regarding a new order for deliveries to the leading European Electronic Toll Service (EETS) provider Toll4Europe of GNSS On-Board Units. Deliveries are scheduled to commence in third quarter. The total order is estimated to around NOK 155 million. “We are grateful for the continued trust from Europe’s leading tolling service provider. This repeat order reflects the strength of our long-term partnership”, says Per Jørgen Weisethaunet CEO of NORBIT.  For further queries, please contact:Per Jørgen Weisethaunet, CEO, +47 959 62 915Per Kristian Reppe, CFO, +47 900 33 203 About NORBIT ASANORBIT is a global provider of tailored technology to selected applications, solving challenges and promoting sustainability through innovative solutions, in line with its mission...

Strasbourg, France, May 22, 2026, 5:45 p.m. CET – The Combined Ordinary and Extraordinary General Meeting of Transgene’s shareholders was held today (May 22, 2026) at 11:00 a.m. CET at the Company’s headquarters (400 boulevard Gonthier d’Andernach – Parc d’Innovation – 67400 Illkirch-Graffenstaden, France). The Combined General Meeting was chaired by Alessandro Riva, Chairman and Chief Executive Officer. In addition to approving the statutory and consolidated financial statements for the fiscal year ended December 31, 2025, and the “Say on Pay” resolutions, the Combined General Meeting was also called to vote on all resolutions submitted to it, notably regarding the renewal of Directors’ terms of office, financial authorizations, and delegations of authority granted to the Board of Directors to operate on the Company’s share capital. All...

Nanterre, 22 May 2026 Publication of the Pitch Book ‘Why invest in VINCI, a global leader in infrastructure’ VINCI announces the publication of its Pitch Book ‘Why invest in VINCI, a global leader in infrastructure’ on its website: Annual reports and presentations | VINCI The main objective of this summary presentation, which is primarily intended for investors, is to highlight the main strengths of the VINCI Group’s business model:key player to capture the world’s megatrends; high and recurring free cash flow; very solid balance sheet; disciplined, clear and value-accretive capital allocation policy; longstanding M&A track record with high returns over time; alignment of interests, between employees – which are collectively the first shareholder of the Group – and other shareholders; outperforming stock over time; shared...

Disclosure of trading in own shares occurred from May 18 to May 21, 2026 Puteaux, May 22, 2026 In accordance with the regulations on share buybacks, in particular Regulation (EU) 2016/1052, Elis hereby declares the purchases of its own shares made from May 18 to May 21, 2026 under the buyback program authorized by the 24th resolution of the General Shareholders’ Meeting of May 22, 2025: Aggregated presentation:Issuer name Issuer code(LEI) Transaction date ISIN Code Daily total Volume (in number of shares) Daily weighted average price of shares acquired (in euros) Platform (MIC Code)ELIS SA 969500UX71LCE8MAY492 05/18/2026 FR0012435121 15,632 26.9968 AQEUELIS SA 969500UX71LCE8MAY492 05/18/2026 FR0012435121 78,668 26.9909 CCXEELIS SA 969500UX71LCE8MAY492 05/18/2026 FR0012435121 12,051 26.9973 TQEXELIS SA 969500UX71LCE8MAY492 05/18/2026 FR0012435121 86,923 26.9924 XPARELIS...